Myasthenia Gravis Market 2019-2025
14-Jan-2019 | Number of pages: 175 | Report Id: BMRC HC 115 | Report Format: | Status: Published

Myasthenia Gravis Market By Treatment Type (Drug Treatment, Rapid Immunotherapies), By End User (Hospitals, Clinics), Industry Analysis, Trends, and Forecast 2019 – 2025

Myasthenia Gravis Market is valued around USD 1168.72 Million in 2018 and expected to reach USD 2280.5 Million by 2025 with the CAGR of 9.9% over the forecast period. Increased demand of effective treatment and increase in research and development activities are the key drivers for Global Myasthenia Gravis Market.

Myasthenia Gravis market report published by the Brandessence Market Research and Consulting Pvt. Ltd. provides the detail information about myasthenia gravis market from various aspects. This report consists of drivers, restrains, Opportunities which help the market to grow over the analysis period and recent trends which support the growth of market. This report consists of regional segmentation with treatment type, end user.

Myasthenia gravis is an autoimmune disorder or neuromuscular disorders which led to the weakening of skeletal muscles. Myasthenia gravis highly affect the muscles which are responsible for breathing, eye movement, swallowing, facial muscles, eyelids and others. The lack of coordination between muscles and nerve cells is one of the major causes of it. It can be diagnosed with the help of blood test which detects the presence of specific antibody or nerve conduction study. Its treatment option includes immunosuppressant, acetylcholinesterase inhibitors and others. In some cases removal of thymus gland improve the patient condition.

Myasthenia Gravis Market Analysis

There are various factors driving the growth of the myasthenia gravis market, one of the major factors driving the growth of the market is increase in the demand of effective treatment for the improvement of patient living condition. As per Myasthenia Gravis Foundation of America report, prevalence of myasthenia gravis in the U.S. is estimated at 14 to 20 per 100,000 population which is around 36,000 to 60,000 cases. Furthermore, increasing research and development activities to develop new and effective therapies for the treatment of myasthenia gravis is expected to supplement the growth of myasthenia gravis market over the forecast period. Moreover, increase in awareness among people is also expected to support the growth of myasthenia gravis market. However, high costs of treatment are expected inhibit the growth of myasthenia gravis market over the forecast period.

Myasthenia Gravis Market Share

Myasthenia Gravis Market Revenue (USD Million) Analysis by Regional and Global, 2019-2025

Global myasthenia gravis market report covers prominent players like Alexion Pharmaceutical Inc., Shire plc, Avadel Pharmaceuticals plc, Baxter International Inc., F. Hoffmann-La Roche AG, Grifols S.A., Novartis AG, CSL Behring, Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals International Inc. and others.

Myasthenia Gravis Market Segmentation –

By Treatment Type

  • Drug Treatment
  • Rapid Immunotherapies

By End User 

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • France
    • Germany
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • Southeast Asia
  • Latin America
    • Brazil
    • Mexico
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Myasthenia Gravis Market Key Players

Shire plc
Alexion Pharmaceutical Inc.
Avadel Pharmaceuticals plc
Baxter International Inc.
F. Hoffmann-La Roche AG
Grifols S.A.
Novartis AG
CSL Behring
Takeda Pharmaceutical Company Limited
Valeant Pharmaceuticals International Inc.

1. Chapter – Report Methodology
1.1. Research Process
1.2. Primary Research
1.3. Secondary Research
1.4. Market Size Estimates
1.5. Data Triangulation
1.6. Forecast Model
1.7. USP’s of Report
1.8. Report Description
2. Chapter – Global Myasthenia Gravis Market Overview: Qualitative Analysis
2.1. Market Introduction
2.2. Executive Summary
2.3. Global Myasthenia Gravis Market Classification
2.4. Market Drivers
2.5. Market Restraints
2.6. Market Opportunity
2.7. Myasthenia Gravis Market: Trends
2.8. Porter’s Five Forces Analysis
2.8.1. Bargaining Power of Suppliers
2.8.2. Bargaining Power of Consumers
2.8.3. Threat of New Entrants
2.8.4. Threat of Substitute Product and Services
2.8.5. Competitive Rivalry within the Industry
2.9. Market Attractiveness Analysis
2.9.1. Market Attractiveness Analysis by Segmentation
2.9.2. Market Attractiveness Analysis by Region
3. Chapter – Global Myasthenia Gravis Market Overview: Quantitative Analysis
3.1. Global Myasthenia Gravis Market Consumption, Market Share ( %) and Growth Rate, 2015-2025
3.2. Global Myasthenia Gravis Market Revenue (USD Million), Market Share (%) and Growth Rate (%), 2015-2025
4. Chapter – Global Myasthenia Gravis Market Analysis: by Treatment Type
5. Chapter – Global Myasthenia Gravis Market Analysis: by End User
6. Chapter – Global Myasthenia Gravis Market Analysis: by Manufacturer
6.1. Global Myasthenia Gravis Market Revenue (USD Million), by Manufacturer, 2015-2018
6.2. Global Myasthenia Gravis Market Consumption, Manufacturer, 2015-2018
6.3. Global Myasthenia Gravis Market Share (%), by Manufacturer, 2018
6.4. Global Myasthenia Gravis Market Price (USD/Unit), by Manufacturer, 2015-2018
6.5. Global Myasthenia Gravis Market Revenue Growth Rate (%), by Manufacturer, 2015-2018
6.6. Merger & Acquisition
6.7. Collaborations and Partnership
6.8. New Product Launch
7. Chapter – Myasthenia Gravis Market: Regional Analysis
7.1. North America
7.1.1. North America Myasthenia Gravis Market Revenue (USD Million) and Growth Rate (%), 2015-2025.
7.1.2. North America Myasthenia Gravis Market Revenue (USD Million) By Country, 2015-2025.
7.1.3. North America Myasthenia Gravis Revenue Market Share (%) By Country, 2015-2025.
7.1.4. North America Myasthenia Gravis Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2015-2025.
7.1.5. North America Myasthenia Gravis Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2015-2025.
7.1.6. North America Myasthenia Gravis Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2015-2025.
7.2. Europe
7.3. Asia Pacific
7.4. Latin America
7.5. Middle East & Africa
8. Chapter – Company Profiles
8.1. Shire plc
8.1.1. Overview
8.1.2. Financials
8.1.3. Product portfolio
8.1.4. Myasthenia Gravis Market Revenue (USD Million), Consumption and Market Share (%), 2015 – 2018
8.1.5. Myasthenia Gravis Sales Market Share (%), 2015 – 2018
8.1.6. Business strategy
8.1.7. Recent developments
8.2. Alexion Pharmaceutical Inc.
8.3. Avadel Pharmaceuticals plc
8.4. Baxter International Inc.
8.5. F. Hoffmann-La Roche AG
8.6. Grifols S.A.
8.7. Novartis AG
8.8. CSL Behring
8.9. Takeda Pharmaceutical Company Limited
8.10. Valeant Pharmaceuticals International Inc.
8.11. Others
9. Chapter – Market Research and Findings

Shire plc
Alexion Pharmaceutical Inc.
Avadel Pharmaceuticals plc
Baxter International Inc.
F. Hoffmann-La Roche AG
Grifols S.A.
Novartis AG
CSL Behring
Takeda Pharmaceutical Company Limited
Valeant Pharmaceuticals International Inc.
Others